HAOHAI BIOTEC Schedules 2025 AGM for 29 May 2026; Agenda Covers Profit Distribution, Director Elections and H-Share Buy-Back Mandate

Bulletin Express
04/28

Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) has issued its proxy form and notice for the 2025 Annual General Meeting, set for 2:00 p.m. on Friday, 29 May 2026 at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai. Key matters requiring shareholder approval are as follows:

1. Routine Business • Board Work Report for 2025 • 2025 Financial Report • 2025 Profit Distribution Plan and authorisation for the Board to declare 2026 interim dividends • Appointment of external auditors for the 2026 financial statements and internal controls

2. Remuneration and Governance • 2026 remuneration plan for directors • Updated Remuneration Management Policies covering directors and senior management

3. Board Composition • Election of Ms. Tian Min as an executive director • Election of three independent non-executive directors—Mr. Chan Sui Yu, Mr. Song Yuanyang and Ms. Xu Duoqi—via cumulative voting

4. Capital Management • Special resolution granting the Board a general mandate to repurchase H shares

Shareholders recorded in the H-share register may appoint proxies by submitting completed forms to the company’s registrar, Computershare Hong Kong Investor Services Limited, by 2:00 p.m. on 28 May 2026. Attendance in person remains an option, in which case previously lodged proxies will be deemed revoked.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10